Drug Trial Radar · NCT04503265
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Last checked: Nov 20, 2026Latest source record: May 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
122
Planned (sponsor's estimate)
Start
Aug 12, 2020
Primary completion
Aug 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- AtlasMedx, IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Aug 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
Conditions
- Advanced Malignant Neoplasm
- Breast Cancer
- Ovarian Cancer
- Homologous Recombination Deficiency
- Prostate Cancer
- Pancreatic Cancer
Interventions
AMXI-5001:Dose Escalation Phase IDrug
Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
AMXI-5001:Dose Expansion Phase IIDrug
Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the Maximum Tolerated Dose (MTD)Time frame: Approximately 12 months
- Determine the Recommended Phase 2 Dose (RP2D) for AMXI-5001 as monotherapyTime frame: Approximately 12 months
- Characterize safety profile of AMXI-5001Time frame: Approximately 24 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology
Los Angeles, California · Recruiting
Johns Hopkins
Baltimore, Maryland · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.